arrow
H

Heike Horn

margarete fischer bosch institute of clinical pharmacology
H指数:34
被引数:6,419

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphoma

通过MYC抑制miR-29会导致转化性滤泡性淋巴瘤中CD40信号增强

Leukemia
IF13.4
2026-02-190
OA
Cyclin D1 rearranged diffuse large B-cell lymphoma—an evolving concept

Cyclin D1 rearranged diffuse large B-cell lymphoma——一个不断发展的概念

Leukemia
IF13.4
2025-11-070
PRE
Cytogenomic and Clinicopathologic Comparison of MYC-Positive and MYC-Negative High-Grade B-Cell Lymphoma With 11q Aberration in the Context of Other Aggressive Lymphomas With MYC Rearrangement

MYC阳性与MYC阴性11q异常的高级别B细胞淋巴瘤的细胞基因组学和临床病理学比较,并与其他具有MYC重排的侵袭性淋巴瘤进行比较

2025-05-100
OAAI
Age- and gender-specific molecular characteristics of diffuse large B-cell lymphoma: Results from clinical trials of the DSHNHL/GLA

弥漫大B细胞淋巴瘤的年龄和性别特异性分子特征:来自DSHNHL/GLA临床 trial 的结果

2025-03-070
OAAI
MicroRNA Expression in High-Grade B-Cell Lymphoma With 11q Aberration

MicroRNA在11q畸变高级别b细胞淋巴瘤中的表达

2025-01-230
OAAI
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress

抑制DLBCL中的glutaminase-1通过促进氧化应激增强维奈托克诱导的抗肿瘤活性

2023-12-131
OAAI
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms
LEUKEMIA
IF13.4
2023-08-105
OAAI
Molecular profiling of EBV associated diffuse large B-cell lymphoma
LEUKEMIA
IF13.4
2023-01-0529
OAAI
Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
2022-09-2613
OAAI
Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas
2022-09-015
OAAI
PARP14 is a novel target in STAT6 mutant follicular lymphoma

PARP14是STAT6突变型滤泡性淋巴瘤的新靶点

LEUKEMIA
IF13.4
2022-07-1810
OAAI
Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma
2021-08-3129
OAAI
MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma
2021-05-0653
OAAI
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial
2021-04-0121
PREAI